Financial Performance - Total revenue for the three months ended July 31, 2024, was 442,830,adecreaseof32.5655,928 for the same period in 2023[5]. - Net loss for the six months ended July 31, 2024, was 3,603,542,comparedtoanetlossof1,844,402 for the same period in 2023, representing an increase in loss of 95.2%[5]. - The company generated total revenue of 851,362forthesixmonthsendedJuly31,2024,comparedto1,132,860 for the same period in 2023, representing a decrease of approximately 25%[31]. - For the six months ended July 31, 2024, the company incurred a net loss from operations of 3,603,542andusedcashflowfromoperationsof2,377,673[19]. - For the three months ended July 31, 2024, the net loss was 1,705,465,indicatingacontinuedtrendoflosses[8].AssetsandLiabilities−TotalassetsasofJuly31,2024,were13,633,709, an increase from 7,517,154asofJanuary31,2024[4].−Totalcurrentliabilitiesincreasedto1,103,590 as of July 31, 2024, compared to 999,093asofJanuary31,2024,reflectingariseof10.512,460,986, with an accumulated deficit of (31,583,561)[8].−ThetotalassetsofthecompanyasofJuly31,2024,were13,633,709, an increase from 9,793,599asofJanuary31,2023,representingagrowthofapproximately396,759,967, compared to 492,942asofJanuary31,2024,indicatingasignificantincrease[4].−Thecompanyreportedacashandcashequivalentsbalanceof6,759,967 as of the end of the period, up from 2,334,553inthepreviousyear[10].−AsofJuly31,2024,theCompanyhadcashandcashequivalentsof6,759,967 and working capital of 6,144,483[19].ResearchandDevelopment−ResearchanddevelopmentexpensesforthethreemonthsendedJuly31,2024,were773,975, an increase of 73.8% from 445,122inthesameperiodof2023[5].−Researchanddevelopmentexpensesfor4PTherapeuticsrosesignificantlyto1,748,510 for the six months ended July 31, 2024, compared to 845,552intheprioryear,markinganincreaseofabout1061,080,329 related to the commercial development and clinical manufacturing agreement with Kindeva Drug Delivery, with an estimated total cost of 8.1million[86].StockandEquity−Totalstockholders′equityasofJuly31,2024,was12,460,986, up from 6,438,235asofJanuary31,2024,showingagrowthof93.58,400,000 during the six months ended July 31, 2024[6]. - The Company completed an 8,400,000equityfinancingwithEuropeaninvestors,whichincludedtworelatedpartiesinvestingatotalof6,420,000[61]. Expenses - Operating expenses for Pocono Pharmaceuticals increased to 321,068forthesixmonthsendedJuly31,2024,comparedto272,283 in the same period in 2023, reflecting an increase of approximately 18%[81]. - The Company recorded interest expenses of 13,637duringthesixmonthsendedJuly31,2024,comparedto12,401 for the same period in 2023[56]. - Depreciation expenses for the six months ended July 31, 2024, were 82,475,comparedto93,936 for the same period in 2023[52]. Legal and Compliance - The company is currently involved in a lawsuit seeking over 500,000indamages,whilealsopursuingcounterclaimsfor1,000,000 against the plaintiffs[89][90]. - The company recorded a reserve for bad debts of 118,675relatedtothebankruptcyproceedingsfromSorrentoTherapeuticsInc.[88].FutureOutlook−Thecompanybelievesitwillgeneratesufficientfundsfromoperationstocontinueasagoingconcernforatleastoneyearfromthedateofthefinancialstatements[20].−TheestimatedcosttocompletethecommercialdevelopmentandclinicalmanufacturingagreementwithKindevaisapproximately8.1 million, with an expected FDA submission in twelve to eighteen months[86].